{"organizations": [], "uuid": "9a1aaadbb6a4723a410d8fb2270296824e8b4914", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180305.html", "section_title": "Archive News &amp; Video for Monday, 05 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-syndax-pharmaceuticals-reports-q4/brief-syndax-pharmaceuticals-reports-q4-loss-per-share-0-80-idUSASB0C8UP", "country": "US", "domain_rank": 408, "title": "BRIEF-Syndax Pharmaceuticals Reports Q4 Loss Per Share $0.80", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.026, "site_type": "news", "published": "2018-03-06T05:36:00.000+02:00", "replies_count": 0, "uuid": "9a1aaadbb6a4723a410d8fb2270296824e8b4914"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-syndax-pharmaceuticals-reports-q4/brief-syndax-pharmaceuticals-reports-q4-loss-per-share-0-80-idUSASB0C8UP", "ord_in_thread": 0, "title": "BRIEF-Syndax Pharmaceuticals Reports Q4 Loss Per Share $0.80", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "syndax pharmaceuticals inc", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "syndax pharmaceuticals", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 5 (Reuters) - Syndax Pharmaceuticals Inc:\n* SYNDAX PHARMACEUTICALS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND PROVIDES CLINICAL AND BUSINESS UPDATE\n* Q4 LOSS PER SHARE $0.80 * SYNDAX PHARMACEUTICALS - FOR Q1 AND FY 2018, TOTAL OPERATING EXPENSES ARE EXPECTED TO BE $22 TO $26 MILLION AND $86 TO $96 MILLION, RESPECTIVELY\n* Q4 EARNINGS PER SHARE VIEW $-0.78 â€” THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-06T05:36:00.000+02:00", "crawled": "2018-03-06T22:27:29.016+02:00", "highlightTitle": ""}